Sector Expert: Yale Jen

Laidlaw & Company

Image: Yale Jen

Dr. Yale Jen joined Laidlaw & Co. in September 2013 as managing director, biotechnology analyst. He has more than 10 years of Wall Street healthcare analyst experience. Prior to joining Laidlaw, he was a senior equity analyst at Roth Capital Partners, focusing on biotechnology. Before that, Jen was a senior equity analyst focusing on biotechnology and Chinese healthcare at Maxim Group. Previously, he was an associate analyst at Rodman and Renshaw and Thomas Weisel Partners, covering large-cap as well as mid- to small-cap biotechnology and specialty pharmaceutical companies. His investment views have been cited in the Wall Street Journal, Bloomberg, Thomson Reuters and Dow Jones Newswire. Before joining Wall Street, Jen spent several years with KPMG Corporate Finance Life Sciences Group and Genesis Group Associates focusing on mergers and acquisitions of healthcare assets, as well as on pipeline optimization for pharmaceutical and biotechnology clients. Jen received his Ph.D. in molecular biology from Cornell Medical School, and his masterís degree in business administration from Rutgers University with a concentration in finance. He holds FINRA licenses 7, 63, 86 and 87.



Recent Quotes

"We expect RNN's three major assets to start Phase 2 studies in H1/16."

— Yale Jen, Laidlaw & Company (11/6/15)
more†>

"We are reiterating our Buy rating for RNN's stock."

— Yale Jen, Laidlaw & Company (11/4/15)
more†>

"We believe RNN's story remains underexposed and the shares are undervalued."

— Yale Jen, Laidlaw & Company (8/10/15)
more†>

"RNN's story remains underexposed and the shares are undervalued."

— Yale Jen, Laidlaw & Company (6/22/15)
more†>

"We are very encouraged by NBY's Q1/15 Avenova sales and expect further growth in 2015 and beyond."

— Yale Jen, Laidlaw & Company (5/20/15)
more†>

"We believe the RNN story remains underexposed and the shares are undervalued."

— Yale Jen, Laidlaw & Company (5/11/15)
more†>

"We believe the RNN story is underexposed and the shares undervalued."

— Yale Jen, Laidlaw & Company (4/21/15)
more†>

"Considering China's unmet medical needs, NBY's NeutroPhase could potentially reach $300M sales."

— Yale Jen, Laidlaw & Company (3/27/15)
more†>



Due to permission requirements, not all quotes are shown.